Perfromance Wealth Partners LLC grew its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 2.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,626 shares of the company’s stock after purchasing an additional 100 shares during the quarter. Perfromance Wealth Partners LLC’s holdings in IDEXX Laboratories were worth $1,499,000 at the end of the most recent reporting period.
Several other large investors have also recently modified their holdings of the business. Mogy Joel R Investment Counsel Inc. boosted its holdings in IDEXX Laboratories by 1.3% in the 4th quarter. Mogy Joel R Investment Counsel Inc. now owns 79,324 shares of the company’s stock worth $32,796,000 after buying an additional 1,010 shares during the period. Atomi Financial Group Inc. lifted its stake in IDEXX Laboratories by 28.4% in the 4th quarter. Atomi Financial Group Inc. now owns 864 shares of the company’s stock worth $357,000 after purchasing an additional 191 shares in the last quarter. Legal Advantage Investments Inc. raised its position in shares of IDEXX Laboratories by 29.7% in the fourth quarter. Legal Advantage Investments Inc. now owns 6,295 shares of the company’s stock worth $2,603,000 after buying an additional 1,440 shares in the last quarter. Seilern Investment Management Ltd bought a new stake in IDEXX Laboratories during the fourth quarter valued at $113,104,000. Finally, Pine Haven Investment Counsel Inc grew its position in IDEXX Laboratories by 10.5% during the fourth quarter. Pine Haven Investment Counsel Inc now owns 1,075 shares of the company’s stock worth $444,000 after buying an additional 102 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.
IDEXX Laboratories Stock Up 1.9 %
Shares of NASDAQ:IDXX opened at $427.33 on Wednesday. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $583.39. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32. The stock’s 50-day moving average price is $423.24 and its 200-day moving average price is $457.45. The stock has a market capitalization of $34.99 billion, a P/E ratio of 41.21, a price-to-earnings-growth ratio of 3.53 and a beta of 1.36.
Insider Activity at IDEXX Laboratories
In related news, Director Sophie V. Vandebroek sold 344 shares of the business’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the transaction, the director now owns 905 shares in the company, valued at $380,498.20. The trade was a 27.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 2.18% of the stock is currently owned by company insiders.
Analyst Upgrades and Downgrades
Several analysts have weighed in on the company. Leerink Partnrs raised IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Piper Sandler reiterated a “neutral” rating and set a $435.00 target price (down from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. Leerink Partners initiated coverage on shares of IDEXX Laboratories in a research report on Monday, December 2nd. They set an “outperform” rating and a $500.00 price objective on the stock. JPMorgan Chase & Co. dropped their price objective on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a report on Friday, October 11th. Finally, StockNews.com raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Thursday, November 28th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $523.86.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
Featured Articles
- Five stocks we like better than IDEXX Laboratories
- What is a Special Dividend?
- SAP’s Strong Momentum: A Bullish Setup for Investors
- Buy P&G Now, Before It Sets A New All-Time High
- BlackRock Breaks Records: Why the Stock Still Has Room to Run
- Stock Market Upgrades: What Are They?
- Duke vs. NRG: Which Energy Stock Will Power Higher Gains?
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.